4 completed, 3 recruiting, 3 terminated, 2 unknown. 9 Phase 1, 6 Phase 2, 2 Not applicable.
Follow KRAS Mutation-Related Tumors: new trials by email Literature Review of KRAS Mutation-Related Tumors trials Research Report on KRAS Mutation-Related Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies Spedox-6, Pegfilgrastim, Filgrastim - Soft-tissue Sarcoma, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | University of California, Irvine | 67 | 2025-04-30 | 2026-07-17 |
| Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC Trametinib, Anlotinib, Tislelizumab - KRAS Mutation-Related Tumors, Advanced Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Chest Hospital | 60 | 2024-07-01 | 2024-06-13 |
| A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours ZG2001 Tosilate Tablets - Solid Tumor, KRAS Mutation-Related Tumors | Phase 1 / Phase 2 | Unknown | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 110 | 2023-08-10 | 2024-03-06 |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm | Phase 1 / Phase 2 | Recruiting | Institut de Recherches Internationales Servier | 554 | 2023-04-18 | 2026-10-13 |
| NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors NEROFE, Doxorubicin - Solid Tumor, KRAS Mutation-Related Tumors | Phase 1 | Recruiting | Georgetown University | 24 | 2023-04-12 | 2026-03-06 |
| Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer BMF-219 - Non Small Cell Lung Cancer, Pancreatic Cancer | Phase 1 | Terminated | Biomea Fusion Inc. | 13 | 2023-01-12 | 2025-02-07 |
| Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies Sensus Smartwatch Application, RX Cap, Fitbit Sense - Lung Cancer, EGFR Gene Mutation | Not applicable | Active not recruiting | University of Virginia | 30 | 2022-08-25 | 2025-11-25 |
| Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers RMC-4630, LY3214996 - Pancreatic Cancer, Colorectal Cancer | Phase 1 | Terminated | The Netherlands Cancer Institute | 24 | 2022-03-31 | 2025-01-24 |
| Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model Collection of surgical waste - Lung Cancer, Lung Adenocarcinoma | Unknown | Central Hospital, Nancy, France | 200 | 2021-11-01 | 2021-11-26 | |
| A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors TPX-0005, Trametinib - KRAS Mutation-Related Tumors, Metastatic Solid Tumor | Phase 1 / Phase 2 | Terminated | Turning Point Therapeutics, Inc. | 9 | 2021-09-23 | 2024-04-02 |
| Patogenic Mutation in 5 Genes co-occuring mutation - Colorectal Cancer, APC Gene Mutation | Completed | Dr Cipto Mangunkusumo General Hospital | 22 | 2021-05-01 | 2021-07-26 | |
| Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer Binimetinib Pill, Hydroxychloroquine Pill - Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 9 | 2021-04-09 | 2025-04-01 |
| A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer ompenaclid, FOLFIRI, Bevacizumab - Gastrointestinal Cancer, Gastrointestinal Neoplasms | Phase 1 | Completed | Inspirna, Inc. | 89 | 2018-06-05 | 2025-04-03 |
| CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer Blood samples - Pancreatic Cancer, Circulating Tumor DNA | Not applicable | Completed | Poitiers University Hospital | 69 | 2016-04-25 | 2020-09-23 |
Carcinoma, Non-Small-Cell Lung (6) · Colorectal Neoplasms (5) · Lung Neoplasms (3) · Pancreatic Neoplasms (3) · Neoplasm Metastasis (2) · Neoplasms (2) · Adenocarcinoma of Lung (1) · Brain Neoplasms (1) · Gastrointestinal Neoplasms (1) · Histiocytosis (1) · Ovarian Neoplasms (1) · Recurrence (1) · Sarcoma (1) · Stomach Neoplasms (1) · Thyroid Neoplasms (1)
Neoplasms (10) · Neoplasms by Site (10) · Lung Diseases (7) · Respiratory Tract Diseases (7) · Respiratory Tract Neoplasms (7) · Thoracic Neoplasms (7) · Bronchial Neoplasms (6) · Carcinoma, Bronchogenic (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Colonic Diseases (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Gastrointestinal Diseases (5) · Intestinal Diseases (5)
IFL protocol (2) · trametinib (2) · 130-nm albumin-bound paclitaxel (1) · Bevacizumab (1) · Blood Specimen Collection (1) · Cetuximab (1) · Doxorubicin (1) · Filgrastim (1) · Folfox protocol (1) · Gemcitabine (1) · Hydroxychloroquine (1) · LY3214996 (1) · Panitumumab (1) · Surveys and Questionnaires (1) · anlotinib (1)
Abramson Cancer Center at Penn Medicine (1) · Biomea Fusion Inc. (1) · Central Hospital, Nancy, France (1) · Dr Cipto Mangunkusumo General Hospital (1) · Georgetown University (1) · Inspirna, Inc. (1) · Institut de Recherches Internationales Servier (1) · Poitiers University Hospital (1) · Shanghai Chest Hospital (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1) · The Netherlands Cancer Institute (1) · Turning Point Therapeutics, Inc. (1) · University of California, Irvine (1) · University of Virginia (1)
United States (8) · China (3) · France (2) · Australia (1) · Denmark (1) · Hong Kong (1) · Indonesia (1) · Italy (1) · Japan (1) · Netherlands (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Baohui Han, MD, PhD (1) · Benjamin Weinberg, MD (1) · Charu Aggarwal, MD (1) · Emile Voest, MD, PhD (1) · Jason Wu (1) · Robert Wasserman, MD (1) · Ryan Gentzler, MD (1) · Steve Morris, MD (1) · Warren Chow, MD (1)
PMID 29808006, PMID 36384095, PMID 37186063, PMID 37308396
2025 (1)